Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19

Repurposing Existing Medicines Is Key Part Of Pandemic Solution, Industry Insists

Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.

Dexamethasone
Dexamethasone has seen positive trial results in COVID-19 patients • Source: Shutterstock

Positive trial results for dexamethasone in treating COVID-19 patients have been welcomed by the off-patent industry as demonstrating the potential for repurposing existing generic medicines to help in the fight against the coronavirus pandemic.

With the World Health Organization citing the results from the UK’s “RECOVERY” – or Randomized Evaluation of COVID-19 Therapy – trial as demonstrating the anti-inflammatory drug to be “the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” off-patent industry leaders have not only praised the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By 

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By 

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”